Trump Reaches Agreements with Pharma Companies to Lower Drug Prices
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump with this weekly recap compiled by The Fly:DRUG PRICES:U.S. President Donald Trumpnine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations, known as the most-favored-nation, or MFN, price. The nine manufacturers include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. The agreements reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, hepatitis B and C, human immunodeficiency virus, and certain cancers, among others. The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies. The agreements ensure foreign nations can no longer use price controls to free ride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market, according to the White House. The agreements require the nine companies to repatriate increased foreign revenue on existing products that they realize as a result of the President's strong America First U.S. trade policies for the benefit of American patients. The agreements also require the nine companies to offer medicines at a deep discount off the list price when selling directly to American patients through TrumpRx.SANCTIONS:Following the Trump administration's approval of a weapons sale to Taiwan, the Chinese government imposed sanctions on 20 U.S. defense companies and 10 of their executives, with targets including Northrop Grumman, Boeing'sdefense unit, and founder of Anduril Industries Palmer Luckey, Stu Woo of The Wall Street Journal report. Beijing intends to freeze the assets of the entities, ban them from Chinese transactions, and prohibit the executives from entering China.TARIFFS: The Trump administration has concluded a semiconductor trade investigation citing harm from China's industry dominance but opted to delay new tariffs, setting an initial zero percent rate on Chinese chip exports for at least 18 months, The New York Times' Ana Swanson. The move reflects efforts to preserve a fragile trade truce with China following earlier tariff escalations and retaliatory measures. Publicly traded companies in the space include AMD, Intel, Marvell, Microchip, Micron, Nvidia, Qualcommand Texas Instruments.CANNABIS RESCHEDULING:President Trump has instructed Attorney General Pam Bondi to finalize a decision on marijuana rescheduling by the end of January, Anthony Martinelli of The Marijuana Herald, citing sources close to the president. An executive order signed by Trump last week directs Bondi to "take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the Controlled Substances Act as quickly as possible, in accordance with federal law." Federal law requires that any change to marijuana's scheduling be formally completed through the Department of Justice. Publicly traded companies in the space include Aurora Cannabis, CV Sciences, Canopy Growth, Cronos Group, Goodness Growth, Green Thumb Industries, IGC Pharma, Tilray, Trees Corporationand Trulieve Cannabis.TRUMP CLASS OF NAVY BATTLESHIPS:President Trump on Monday announced plans to build a new fleet of Navy battleships, anchoring what he called the Pentagon's "Golden Fleet," CBS News' Kathryn Watson. The president said he approved plans to begin constructing "two brand-new, very large, largest we've ever built, battleships." He later said he expects to build a total of 10 ships in short order, and ultimately 20 to 25. He made the announcement flanked by renderings of ships that were referred to as "Trump class." Shares of Huntington Ingallstraded up following the news.NEW YORK TIMES:President Trump, in a social media, said, "The Failing New York Times, and their lies and purposeful misrepresentations, is a serious threat to the National Security of our Nation. Their Radical Left, Unhinged Behavior, writing FAKE Articles and Opinions in a never ending way, must be dealt with and stopped. THEY ARE A TRUE ENEMY OF THE PEOPLE! Thank you for you attention to this matter."
Trade with 70% Backtested Accuracy
Analyst Views on IGC
About IGC
About the author

- Surge in Acquisition Proposals: ZIM Integrated Shipping has received multiple competitive acquisition proposals during its strategic review, with the board evaluating these offers to create significant value for shareholders, which is expected to enhance the company's market appeal.
- Stock Price Rebound: Following the announcement, ZIM's shares rose 7.6% in pre-market trading to $21.38, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Enhanced Strategic Value: By actively assessing acquisition proposals, ZIM not only strengthens its market position but also may achieve operational efficiencies through resource integration, thereby delivering higher returns to shareholders.
- Positive Market Reaction: The stock price increase indicates investor confidence in ZIM's potential acquisitions, which could further boost the company's competitiveness and market share in the shipping industry.

Trial Progress: IGC Pharma has achieved 65% patient enrollment in its Phase 2 CALMA trial for IGC-AD1, aimed at treating agitation in Alzheimer's disease, with a target of 146 participants.
Agitation in Alzheimer's: Agitation affects over 76% of Alzheimer's patients, leading to significant distress for both patients and caregivers, highlighting the need for new treatment options.
Therapeutic Potential: Interim analyses of IGC-AD1 have shown significant reductions in agitation, indicating its potential as a novel therapy for Alzheimer's dementia.
Recruitment Strategy: The trial's enrollment has been enhanced through a hybrid strategy, with 25% of participants recruited via social media and 75% through clinical sites, aiming for full enrollment by early 2026.

Earnings Reports Overview: Several companies, including H World Group Limited, Aramark, and Full Truck Alliance Co. Ltd., are set to report earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
H World Group Limited (HTHT): Expected earnings per share (EPS) of $0.60, a 3.45% increase year-over-year, with a Price to Earnings (P/E) ratio of 23.31.
Aramark (ARMK): Forecasted EPS of $0.65, a 20.37% increase from last year, and a P/E ratio of 20.28, indicating stronger growth compared to industry peers.
Negative Earnings Forecasts: Companies like JinkoSolar Holding Company Limited and Freightos Limited are projected to report significant decreases in EPS, with JinkoSolar expected to have a P/E ratio of -2.49, reflecting ongoing challenges.

Quarterly Performance: IGC Pharma, Inc. reported a quarterly loss of $0.02 per share, matching the Zacks Consensus Estimate, and revenues of $0.19 million, which fell short of expectations by 56.59%.
Earnings Outlook: The company's earnings outlook is mixed, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market, while future earnings estimates remain uncertain.
Industry Context: The Medical - Drugs industry, where IGC operates, ranks in the top 34% of Zacks industries, suggesting that industry performance could significantly influence IGC's stock movement.
Comparative Analysis: MediWound, a competitor in the same industry, is set to report its quarterly results soon, with expectations of a loss and increased revenues, highlighting the competitive landscape IGC is navigating.

Zacks Rank Upgrade: IGC Pharma, Inc. has received a Zacks Rank #1 (Strong Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks Consensus Estimate for IGC has risen by 27.3% over the past three months, reflecting analysts' growing confidence in the company's future earnings potential.
Investment Strategy: The Zacks rating system, which maintains a balanced approach to stock ratings, positions IGC in the top 5% of stocks based on earnings estimate revisions, suggesting it could outperform the market.
Market Potential: IGC Pharma is well-positioned to capitalize on the booming semiconductor market, projected to grow significantly, driven by demand in Artificial Intelligence, Machine Learning, and the Internet of Things.
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including IGC Pharma, SCOR SE, Royal Bank of Canada, Universal Insurance Holdings, and Avino Silver & Gold Mines, all showing significant increases in earnings estimates over the past 60 days.
Semiconductor Market Growth: A lesser-known company in the semiconductor sector is poised for growth, targeting the rising demand for Artificial Intelligence, Machine Learning, and Internet of Things, with the global semiconductor market expected to nearly double by 2028.







